This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Editorial

. 2024 Feb 29;143(9):741-742.

doi: 10.1182/blood.2023023108.

Toward a cure for cHL without chemotherapy

Affiliations

PMID: 38421817
DOI: 10.1182/blood.2023023108

Free article

Editorial

Toward a cure for cHL without chemotherapy

Ryan C Lynch. Blood. 2024.

Free article

. 2024 Feb 29;143(9):741-742.

doi: 10.1182/blood.2023023108.

Author

Affiliation

¹ University of Washington and Fred Hutchinson Cancer Center.

PMID: 38421817
DOI: 10.1182/blood.2023023108

No abstract available

PubMed Disclaimer

Comment on

Brentuximab vedotin with dacarbazine or nivolumab as frontline cHL therapy for older patients ineligible for chemotherapy.
Friedberg JW, Bordoni R, Patel-Donnelly D, Larson T, Goldschmidt J, Boccia R, Cline VJM, Mamidipalli A, Liu J, Akyol A, Yasenchak CA. Friedberg JW, et al. Blood. 2024 Feb 29;143(9):786-795. doi: 10.1182/blood.2022019536. Blood. 2024. PMID: 37946283 Clinical Trial.

References

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Elsevier Science
- Silverchair Information Systems
Medical
- MedlinePlus Health Information